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pain syndromes (CRPS) and inﬂammatory and sympathetic parameters.
Patients and methods: Twenty one CRPS patients and 15 healthy controls were examined. Clin-
ical data, sympathetic skin response (SSR), TNFa and normetanephrine were evaluated.
Results: Fourteen patients had increased serum TNFa which showed signiﬁcant relationship
with some clinical parameters. Three patients had increased normetanephrine. Mean SSR latency
was shortened in patients. No signiﬁcant relationship between SSR and sweating manifestations
and no correlation between serum normetanephrine, SSR, and serum TNFa were found.
Conclusion: Inﬂammation plays a major role and SSR is enhanced in CRPS.
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Complex regional pain syndromes (CRPS) describe an array of
painful conditions that are characterized by continuous spon-
taneous regional pain seemingly disproportionate in time or
degree to the usual course of any known trauma or other le-
sion. The pain is regional and usually has a distal predomi-
nance of abnormal sensory, motor, sudomotor, vasomotor
and/or trophic ﬁndings [1].
There are two distinct subtypes of CRPS. CRPS type I
which occurs typically without a distinct major nerve lesion.
It may take place after trauma, stroke or myocardial infarction
[2,3]. In CRPS type II there is a major nerve damage, i.e., a
partial lesion of a peripheral nerve is necessary for the diagno-
sis [4].
122 N.A. El Sawy et al.Several pathophysiological mechanisms have been proposed
to explain CRPS. These mechanisms include, facilitated neuro-
genic inﬂammation [5], pathological sympatho-afferent cou-
pling [6], neuroplastic changes within the CNS [7,8] and
genetic factors [9]. Inﬂammation has been proposed as a mech-
anism for CRPS because many clinical symptoms of acute
CRPS resemble inﬂammation [10]. Neurogenic inﬂammation
is mediated by traumatically released nerve growth factor
(NGF) and cytokines with consequent nociceptive C ﬁbers
sensitization and production of substance P (SP) as well as cal-
citonin gene-related peptide (CGRP) [11,12]. However, inﬂam-
mation in CRPS may not always be neurogenic in nature.
Regional local inﬂammation was demonstrated in patients with
CRPSI as evidenced by increased TNFa and interleukin 4 with-
out a concomitant increase of neuropeptides [13].
Sympathetic dysfunction in CRPS has been addressed [14–
26]. Skin temperature abnormalities have been attributed to
either inhibition of norepinephrine-mediated sympathetic con-
trol over cutaneous blood vessels [19,20] (as in the acute stage)
or their supersensitivity to circulating catecholamines [21–23]
(as in the chronic stage with vasoconstriction). In addition,
abnormal sudomotor function was also found in CRPS pa-
tients [24–26]. Patients with sympathetically mediated pain
(CRPSII) are suggested to have sympathetic-afferent coupling
[18,27,28] triggered by NGF and TNFa in response to periph-
eral nerve lesion [28–30]. Such coupling may be responsible for
the sensitization of the C nociceptive neurons mediated by lo-
cally released norepinephrine and epinephrine [29]. In CRPSI,
similar coupling may take place [16–18,27] as a result of sub-
clinical traumatic nerve lesions of the cutaneous and deep so-
matic tissues [31–32]. Moreover, in CRPS type I, sympathetic
nerve terminals in peripheral tissues may serve as mediator ele-
ments in hyperalgesia and inﬂammation through a mechanism
which is largely independent of activity in the sympathetic neu-
rons. It is triggered by inﬂammatory mediators as TNFa which
lead to synthesis and release of prostaglandin E2 from sympa-
thetic terminal or in association with it leading to sensitization
of nociceptive afferents for mechanical stimuli and venular
plasma extravasation, i.e., sympathetically mediated neuro-
genic inﬂammation [28].
Sympathetic dysfunction [14–26], TNFa serum or blister
[13,33] or soluble TNF receptor [5] levels have been sepa-
rately investigated. However, the relative contribution of
the inﬂammatory mechanisms and sympathetic dysfunction
to the clinical features of the disease is not clearly
identiﬁed.
The aim of this work was to study the relationship between
the clinical pattern of CRPS and the inﬂammatory factors as
well as sympathetic dysfunction. Identifying such a relation-
ship is a prerequisite for a mechanism-oriented therapy [34].
Study design: Case-control cross-sectional study.2. Patients and methods
Twenty one CRPS patients who attended the outpatient clinic
of Department of Physical Medicine, Rheumatology and
Rehabilitation, Faculty of Medicine, Alexandria University,
were included in the study after signing an informed consent
and informed about the details of the procedures. In addition,
15 age matched controls for the electrophysilogical study were
included. The study was approved by the local ethical commit-tee of Faculty of Medicine, Alexandria University. Patients
were diagnosed according to the revised Budapest criteria (re-
search diagnostic criteria), 2004 [1]. Patients were excluded
from the study if one or more of the following were present:
hypertension as it affects the level of catecholamines [35], dis-
eases that produce features like CRPS as diabetes mellitus,
peripheral neuropathy, vascular disorders as Raynaud’s phe-
nomenon and any concomitant infection or inﬂammatory dis-
ease as it interferes with the level of TNFa, acute phase
proteins and blood picture [5], intake of drugs that affect the
vascular system, corticosteroids and immunosuppressive drugs
[20,33] and delayed bone healing [5]. Moreover, smokers were
also excluded from the study [5]. Each patient was subjected to
(a) full history taking regarding the etiology of CRPS (whether
injury to a major nerve, any painful condition of the limb or
immobilization), local symptoms of the affected hand, dura-
tion of hand complaints, the causative agent and the pre-
scribed treatment (whether physical or medical). (b) Any
medical reports or documents that clarify the etiology of
CRPS (electrophysiological study, plain X ray etc) were con-
sidered to determine the subtype of CRPS (I or II). (c) Patients
were then subjected to local hand examination (where the diag-
nostic criteria were determined for each case), together with
general physical and neurological examination.
Symptoms and signs of CRPS were assessed as follows:
(a) Pain severity was assessed by Visual Analogue Scale
(VAS) [36,37] with respect to the hand use in activities
of daily living.
(b) Skin temperature asymmetry was detected as follows:
the dorsum of the involved and uninvolved hands of
the patient were felt by the dorsum of the examiner’s
hand and reported as a qualitative data (present or not)
(c) Sweating asymmetry was detected as well, i.e., the palm
of the involved and uninvolved hands of the patient were
felt by the examiner’s hand and sweating asymmetry was
reported as present or not.
(d) The volume of the hand (for quantiﬁcation of edema)
was determined by measuring the volume of the water
displaced in milliliters by immersion of the tested hand
in a scaled container [33,38] till the level of the unlar sty-
loid process. Then the difference between the involved
and uninvolved extremity was calculated.
(e) Motor dysfunction was determined as follows:– Grip and pinch strength were measured by a hand-
held dynamometer (Preston hand dynamometer and
pinch gauge) in kilograms for the involved and uni-
nvolved hands.
– Active range of motion was measured by a goniome-
ter for the wrist ﬂexion and extension, metacarpo-
phalangeal, and interphalangeal joints ﬂexion and
extension for the most restricted digit [33] in the st-
andard positions [39] and expressed as an absolute
value in degrees.(f) Electrophysiological study:Sympathetic skin response
was performed for the affected hands of the patients
as well as the hands of controls [40] as a measure for
sympathetic function using NIHON KOHDEN (Neuro-
pack) electrophysiological apparatus. The cutoff value
of the latency was determined by calculating the
mean ± 2SD of the controls. The abnormality of SSR
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ence of abnormal latency (shortened or prolonged)
because the latency was considered to be a reproducible
and effective parameter to detect SSR abnormalities by
some authors [41,42].
(g) Laboratory investigations:
– Serum TNFa was detected in patients by chemilumines-
cence technique using IMMULIT 1000-Siemens. The nor-
mal level was up to 8.1 ng/ml.
– Normetanephrine (NMN) was detected in patients using
Metanephrine ELISA Kit, (plasma) from DRG Interna-
tional, Inc. The normal level was <200 pg/ml.
– CRP and complete blood count with differential leucocytic
count were also assessed in patients.
The blood samples were obtained from the venous blood
taken from the veins at the dorsum of the affected hands of
the patients [20].
Statistics. Description of the sample was expressed as fre-
quencies and percentages. Skewness of the measured variables
was assessed to determine normality of distribution. Mann–
Whitney test was used for in-between group comparisons. Cor-
relations between quantitative variables were detected by
Spearman’s test. The statistical relationships between qualita-
tive variables were detected by Chi square test. SPSS v 11.0
was used to perform the statistical analysis. Cut off values were
calculated as the mean ± 2SD of controls for the SSR. Pa-
tients who had serum levels of TNFa and NMN exceeding
the upper limit of normality were considered abnormal.
3. Results
The study included 21 patients with CRPS; 14 patients (66.7%)
had type I and seven patients (33.3%) had type II. Type I
occurred as a consequence of distal upper limb fractures (12
cases; 57.14%), repaired extensor digitorum tendon and oper-
ated ganglion on the dorsal aspect of the wrist (one case each;
9.52%), while type II took place following gross partial nerve
injuries including ulnar nerve at the wrist (three cases; 14.29%)
and one case for each of the following injuries: superﬁcial ra-
dial nerve, brachial plexus, triple nerve injuries (median, ulnar
and radial) as well as a painful neuroma due to old ulnar nerve
injury at the wrist (total = four; 19%). Sixteen patientsTable 1a Clinical features, laboratory and electrophysiological par
Parameters Subgroups
Aﬀected hand m
Pinch strength (kg) 0.75 ± 0.8
Grip strength (kg) 1.42 ± 2.5
Hand volume (mL) 547.33 ± 161.56
Volume diﬀerence of both hands (mL) 40.67 ± 30.81
VAS for ADL (mm) 64.67 ± 35.23
VAS for pain (mm) 58.58 ± 35.46
Serum TNFa (ng/mL) (normally up to 8.1) 9.61 ± 5.47
Serum normetanephrine (pg/mL) (normally < 200) 149.16 ± 163.1
VAS = visual analogue scale, mL = milliliter, kg = kilogram, AD
mg/L = milligram/liter, mm= millimeter, ng/mL= nanogram/milliliter,
* p is signiﬁcant if <0.05.(76.2%) were females and ﬁve (23.8%) were males. Their mean
age was 43 ± 15.17 years (ranging from 17 to 61) and the
mean disease duration was 3.75 ± 2.21 months (ranging from
1 to 7). Twenty patients had different combinations of mani-
festations suggestive of acute (warm) CRPS while only one pa-
tient (4.76%) had primary cold CRPS with bluish hand
discoloration, decreased local temperature and increased
sweating of seven month duration.
All patients complained of continuing diffuse hand pain
usually awakening the patient from sleep (in CRPS type II pa-
tients, pain was not restricted to the territory of the injured
nerve apart from the patient with the injured superﬁcial radial
nerve whose pain was limited to the dorsum of the hand). Pain
was expressed as either lancinating, burning, cutting, electric
or sawing.
The mean CRP was 6.48 ± 5 mg/L (normally up to 6),
while the mean leucocytic count was 8423.8 ± 2576.2 cell/
cumm (normally up to 11,000). All patients had normal leuco-
cytic count (thus infection was excluded).
The study also included 15 healthy controls for the SSR.
There was no statistically signiﬁcant difference between pa-
tients and controls regarding age.
Tables 1a and 1b show the clinical features, relevant labo-
ratory data and electrophysiological parameters of the studied
CRPS patients. There was a statistically signiﬁcant decrease of
both mean pinch and grip strengths as well as an increase of
the mean volume of the affected compared to non-affected
hands of CRPS patients. There was also a signiﬁcant decrease
of the mean SSR latency of the affected hands of patients
(0.99 ± 0.19 s) compared to controls (1.26 ± 0.18 s)
(Z= 3.581, p= 0.001, limits of normality ranged from 0.9
to 1.62 s).
It is to be mentioned that the three patients (14.29%) who
had increased serum NMN had also increased serum level of
TNFa. Moreover, the seven patients (33.33%) with normal
serum level of TNFa had also normal serum level of NMN.
Table 2 shows no signiﬁcant differences between type 1 and
II CRPS regarding hand manifestations, impact of the disease
on ADL, laboratory and SSR ﬁndings.
Matching between sweating manifestations among the
studied patients and the results of their sympathetic skin re-
sponse (SSR) revealed that seven patients (33.33%) had nor-
mal sweating manifestations [six (28.57%, had normal SSRameters of the studied CRPS patients.
Z p
ean ± SD Non-aﬀected hand mean ± SD
4.4 ± 2.18 3.297 0.001*
22.12 ± 10.74 3.181 0.001*
506.67 ± 170.62 3.19 0.001*
L: activity of daily living, SSR = sympathetic skin response,
pg/mL = pico gram/milliliter, s = second.
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124 N.A. El Sawy et al.latency and one (4.76% had enhanced response, i.e., short la-
tency]. Moreover, 11 patients (52.38%) had excessive sweating
on clinical examination [seven (33.33%) had normal SSR la-
tency and four (19.1%) had enhanced response]. Accordingly,
eight patients had a discrepancy between sweating manifesta-
tions as detected clinically and the outcome of the SSR. On
the other hand, only three patients (14.29%) had impaired
sweating (decreased sweating or dry skin) and all had unob-
tainable SSR. There was no statistically signiﬁcant association
between sweating manifestations and SSR ﬁndings (Chi
square = 0.101, p= 0.751).
In Table 3, patients with increased serum level of TNFa
showed signiﬁcant increase in the hand volume difference
and hence increased edema compared to those with normal
TNFa.
In Table 4 increased TNFa in CRPS patients is signiﬁcantly
associated with skin color changes, hand edema, sweating and
temperature asymmetries reﬂecting its probable pathogenic
role with respect to these clinical features of such patients while
SSR abnormality is not associated with any of them.
No correlation was found between serum normetanephrine
level and each of the following: serum TNFa, any of the clin-
ical parameters and SSR parameters.4. Discussion
Despite of the diagnostic distinction between CRPS type I and
II, the lack of signiﬁcant difference in terms of clinical, labora-
tory and SSR is suggestive of signiﬁcant pathophysiologic sim-
ilarities. This is in agreement with the results of other studies
and the proposed existence of a form of triggering nerve trau-
ma in type I CRPS [1,43]. Low density of nociceptive C and Ad
ﬁbers in CRPS I provide further support of such pathophysio-
logic similarity [31,32].
A localized inﬂammatory process (peripheral afferent mech-
anism) [13,44] as well as autonomic abnormalities (peripheral
efferent mechanism) [14–18,45] are among the proposed patho-
genic mechanisms of CRPS.
In the present study, TNFa was found elevated in 2/3 of the
studied patients. This reﬂects a signiﬁcant inﬂammatory com-
ponent of the pathogenic mechanism. TNFa is a key cytokine
contributing to CRPS features [46,47]. Tissue injury leads to
production of TNFa (which also induces other proinﬂamma-
tory cytokines) [47] by endothelial cells, ﬁbroblasts, lympho-
cytes and tissue macrophages [48] which can lead to
sensitization of nociceptors and ampliﬁcation of neurogenic
inﬂammation [11]. Proinﬂammatory cytokines can be operant
in CRPS independent of neurogenic inﬂammation [13]. The in-
creased TNFa level in CRPS patients was proved in many stud-
ies whether in patients’ sera [38,49] or locally in blister ﬂuid
[13,33]. However, in a study performed by van de Beek et al.
[50], serum TNFa was within-normal limits in CRPS patients.
This is in agreement of one-third of our patients who had nor-
mal serum TNFa indicating that inﬂammation might not con-
tribute to the pathogenesis of CRPS in those patients. The
inﬂuence of disease duration is unlikely to explain the normal-
ity of TNFa in our study because the range of disease duration
was 1–7 months which represents the initial (up to one year)
stage of CRPS. Serum TNFa was found elevated in the initial
and intermediate stages (up to 40 months) by other researchers
[33,38]. Moreover, there was no correlation between serum
Table 2 Comparison between patients with type I and type II CRPS regarding selected clinical characteristics, laboratory ﬁndings and
SSR parameters (Mann–Whitney test).
Parameter CRPS type I (n= 14) Mean ± SD CRPS type II (n= 7) Mean ± SD Z p
Clinical
Age (years) 47.36 ± 14.38 34.29 ± 13.63 2.057 0.04*
Disease duration (months) 3.71 ± 2.3 3.83 ± 2.23 0.286 0.775
VAS for pain. 62.92 ± 36 51.14 ± 36 0.552 0.581
Aﬀected hand volume (mL) 538.18 ± 159.86 572.5 ± 188.39 0.396 0.692
Hands volume diﬀerence (mL) 40.91 ± 28.1 40 ± 42.43 0.000 1
Aﬀected pinch strength (kg) 0.97 ± 0.84 0.2 ± 0.28 1.853 0.064
Aﬀected grip strength (kg) 1.83 ± 2.92 0.5 ± 1 1.008 0.313
VAS for ADL 77.5 ± 26.3 54.4 ± 40.83 1.246 0.213
Laboratory
CRP (mg/L) 5.57 ± 4.32 7.96 ± 6.26 0.784 0.433
Leucocytic count 7607.14 ± 2144.57 10057.14 ± 2736.7 1.791 0.073
TNFa (ng/mL) 10.62 ± 6.45 7.6 ± 1.52 1.493 0.136
Normetanephrine (pg/mL) 166.62 ± 193.6 111.33 ± 57.21 0.132 0.895
SSR (aﬀected hand)
Latency (S) 0.98 ± 0.19 0.99 ± 0.21 0.422 0.673
VAS = visual analogue scale, ADL= activity of daily living, SSR = sympathetic skin response, mg/L = milligram/liter, mm=millimeter,
ng/mL= nano gram/milliliter, pg/mL= pico gram/milliliter, s = second, lV=microvolt.
* p is signiﬁcant if < 0.05.
Table 3 Comparison between patients with increased (›) and normal TNFa regarding selected clinical characteristics, laboratory
ﬁndings and SSR parameters (Mann–Whitney test).
Parameter Patients with › TNFa (n= 14)
Mean ± SD
Patients with normal TNFa (n= 7)
Mean ± SD
Z p
Clinical
Age (years) 42.93 ± 15.1 43.14 ± 16.51 0.000 1
Disease duration
(months)
3.21 ± 2.25 4 ± 1.63 0.736 0.462
VAS for pain. 65.83 ± 38.41 46.14 ± 28 1.273 0.203
Aﬀected hand volume
(mL)
529.17 ± 155.59 620 ± 199.25 1.093 0.274
Hands volume
diﬀerence (mL)
48.33 ± 28.87 10 ± 17.32 2.041 0.041*
Aﬀected pinch strength
(kg)
0.77 ± 0.88 0.67 ± 0.5 0.314 0.754
Aﬀected grip strength
(kg)
1.35 ± 2.81 1.67 ± 1.53 0.920 0.357
VAS for ADL 62.86 ± 36.84 71 ± 41 0.298 0.766
Laboratory
CRP (mg/L) 6.43 ± 5.57 6.6 ± 4 0.56 0.576
Leucocytic count (cell/
cumm)
8150 ± 2835.15 8971.43 ± 2045.1 0.672 0.502
Normetanephrine (pg/
mL)
166.46 ± 193.66 111.67 ± 57.15 0.044 0.965
SSR (aﬀected hand)
Latency (s) 1 ± 0.21 0.93 ± 0.15 0.609 0.542
VAS = visual analogue scale, ADL= activity of daily living, SSR = sympathetic skin response, mg/L = milligram/litre, mm=millimeter,
pg/mL= pico gram/milliliter, s = second, lV=microvolt.
* p is signiﬁcant if < 0.05.
Complex regional pain syndromes: Clinical characteristics and pathophysiological factors 125TNFa level and disease duration in our study (this was also
proved by Wesseldijk et al. [49]). Also there was no signiﬁcant
difference between patients with elevated serum TNFa and
those without regarding disease duration in our study. How-
ever, Huygen et al found serum TNFa to be normal in their pa-tients while elevated in suction blister ﬂuid in the affected side
representing strictly local inﬂammation [13]. This may explain
the normality of serum TNFa among some of our patients
and if so, inﬂammation can still be considered as an operating
mechanism of such patients.
Table 4 Association between increased TNFa and SSR
abnormalities with local hand manifestations of CRPS patients.
Variables Increased TNFa Abnormal SSR
Chi-square p Chi-square p
Sweating asymmetry 6.857 0.009* 0.101 0.751
Hand edema 6.431 0.011* 0.991 0.340
Temp. asymmetry 4.947 0.026* 0.940 0.332
Skin color changes 4.677 0.031* 0.029 0.864
* p is signiﬁcant if < 0.05. Temp. = temperature.
126 N.A. El Sawy et al.Comparison between patients with normal and increased
serum TNFa revealed signiﬁcant increase in hand edema in
the latter group. Moreover, elevated serum TNFa showed sig-
niﬁcant association with changed skin color, temperature,
sweating asymmetry and nail changes as well as hand edema
in contrast to another set of features including pain severity,
hand weakness and movements and impact on daily activities;
all of which showed no signiﬁcant relation to elevated serum
TNFa. Accordingly, while inﬂammation in general could ex-
plain some major disease features, TNFa as a marker may
not explain other features. In the present study markers of neu-
rogenic inﬂammation were not assessed. Neurogenic inﬂam-
mation may account for these features not explained by the
elevated TNFa as well as those explained by elevated TNFa
[50,51]. One should note that TNFa itself is a triggering factor
of neurogenic inﬂammatory pathway. Neurogenic inﬂamma-
tion was found to play a role in sweating abnormalities in
CRPS patients as concluded by Kumazawa et al through
CGRP and SP [52].
Normetanephrine provides a monitor of norepinephrine
(NE) release during regional sympathetic nervous system acti-
vation, as it depends on NE spillover (not under resting condi-
tions) [53–55]. Unlike several studies which demonstrated
lowered serum NE [14,15,20]. The majority of our patients
(18) had normal serum NMN level denoting normal secretion
of NE (about 80% of which by sympathetic postganglionic
vasoconstrictor terminals to muscles and skin) [20] and lack
of sympathetic overactivity. Rather, this reﬂects adaptive
supersensitivity due to disruption of efferent sympathetic mod-
ulation [14,20,56]. However, only 3 of our patients (all of type I
CRPS) had increased plasma NMN level denoting NE spill-
over due to sympathetic over activity. None of the available lit-
erature found increased NE or its metabolite in CRPS patients
apart from Wasner et al. [15]who had one patient with CRPS I
with increased serum NE in the affected limb compared to
unaffected one. Our 3 patients had also increased plasma
TNFa. This might suggest combined inﬂammatory process
and sympathetic overactivity as underlying mechanisms for
CRPS. Collectively, the overall clinical features were common
among those patients with increased serum NMN and those
without and some of their features can not be explained by
sympathetic overactivity as local increase of temperature, ede-
ma and redness of the skin implying that the inﬂammatory fac-
tors might have an upper hand in the clinical manifestations of
those patients.
Seven patients (4 with type II and 3 with type I CRPS) had
normal serum levels of TNFa and NMN. The likelihood of
inﬂammation to be the underlying mechanism is decreased un-
less its presence was restricted to the blister ﬂuid [13,33]or theinﬂammation in such patients is neurogenic in origin with nor-
mal proﬁle of classic innate inﬂammatory cytokines as TNFa
[50] a condition which may be associated with the release of
neuropeptides from primary afferents into peripheral tissue
[57]. The normality of NMN does not exclude entirely the role
of sympathetic dysfunction in CRPS because following nerve
trauma (whether overt in type II or subtle in type I) adrenergic
receptors are expressed on nociceptive ﬁbers [6,58], and con-
tribute to sympatho-afferent coupling through which sympa-
thetic activity can increase spontaneous pain and the spatial
extent of hyperalgesia, i.e., sympathetically mediated pain
[18]. Finally, the laboratory proﬁle of the single patient (type
II) who presented by the ‘‘cold’’ CRPS revealed normal serum
NMN as well as increased serum TNFa. This may be ex-
plained in terms of alpha adrenergic denervation supersensitiv-
ity of sweat glands (SG) and cutaneous blood vessels to
circulating catecholamines (released in response to life stress
or pain itself) leading to excessive sweating and vasoconstric-
tion [23]. Neurogenic inﬂammation can also account for this
presentation as increased TNFa tends to stimulate the release
of a potent vasoconstrictor neuropeptide, endothelin-1 in pa-
tients with CRPS [59].
In the present study NMN had no correlation or associa-
tion with any of the disease parameters. It did not show differ-
ence between patients with normal and increased TNFa or
patients with type I or II CRPS. This makes the contribution
of sympathetic over activity via the cutaneous and muscular
blood vessels to the pathogenesis of CRPS [20] in our study
a far possibility.
In the context of assessment of autonomic dysfunction, the
studied patients signiﬁcantly differed from control in having
shorter SSR. Similar ﬁndings have been shown by Drory
et al justifying their recommendation of SSR as a useful com-
plementary method in diagnosing reﬂex sympathetic dystrophy
[60]. Shortening of SSR latency has been considered to reﬂect
enhanced SSR [24]. In our study the latency of SSR was used
for interpretation because it depends on the integrity of the
innervation of the SG and even if potentials of very few axons
were recorded they would be enough to reﬂect the latency of
response [42] while several factors may render the amplitude
difﬁcult to interpret [61,62] especially in CRPS.
Several studies assessed SSR in CRPS [24,26,63–66]. It was
found to be increased in acute disease [24,65,66], normalized
after therapy [24,66] while in the chronic conditions it was de-
creased or unobtainable [63]. The lack of consistency or signif-
icant association between sweating manifestation and SSR
among the studied patients raised the possibility that the mech-
anism (s) controlling clinical sweating may differ from those
responsible for the SSR in CRPS. Abnormal local sweating
in CRPS may be attributed to several mechanisms [23,52,67]
including non-sympathetically mediated ones as inﬂammation.
The latter may involve CGRP which is found in the SG them-
selves or co-localized with acetylcholine in sudomotor axons
[68]. CGRP per se does not induce sweating [52] but induces
a stronger sweat response as it enhances sweat production in
single SG [52,69]. Substance P is another inﬂammatory prod-
uct that potentially may contribute to decreased sweating
through non-sympathetically mediated mechanism [52,70].
However, in the present study, the relationship between abnor-
mal SSR and abnormal sweating is still well recognized as ob-
served in those patients with dry hands or with decreased
sweating who showed associated un-obtainable SSR that is
Complex regional pain syndromes: Clinical characteristics and pathophysiological factors 127probably relevant to nerve injury as in CRPS II or an initial
nerve trauma in CRPS I with injury of the un-myelinated C-
ﬁbers. Both inﬂammatory and sympathetically mediated fac-
tors, thus, seem to interplay, resulting into abnormal sweating
manifestations in CRPS patients.
In the present study, the studied parameters of sympathetic
function (SSR and serum NMN) varied differently among the
studied patients with no mutual signiﬁcant association, a ﬁnd-
ing that is probably explained by differential involvement of
the cholinergic and adrenergic sympathetic components in
CRPS [71]. Thus detection of sympathetic dysfunction in
CRPS may necessitate investigating both systems.
Taken together, analysis of the clinical as well as the labo-
ratory ﬁndings of the studied sample reveals a general trend
favoring inﬂammation as a pathogenic mechanism (based on
increased TNFa, normal NMN and relevant clinical presenta-
tion). However, in some patients with normal laboratory ﬁnd-
ings no solid conclusions could be derived and all mechanisms
could be employed equivocally to explain the clinical ﬁndings.
This imposes a great challenge in managing such patients and
requires too many laboratory markers to search for. In such
impractical puzzling situation the physician may be obliged
to treat the patient empirically.
From this study it may be concluded that inﬂammation
plays a major role in the pathogenesis of CRPS while the role
of sympathetic dysfunction could not be clearly deﬁned prob-
ably because the different mechanisms [15,19,20,25,71] of sym-
pathetic dysfunction in CRPS were not tested in this study.
This can be accepted if CRPS is considered as a dynamic pro-
cess affecting multiple parts of the nervous system rather than
to be a static, single-factor disease [12]. However, based on the
results of this study, TNFa is recommended as a marker of
inﬂammation in CRPS and SSR as a marker for sympathetic
dysfunction combined with meticulous analysis of the clinical
manifestations in a trial to ﬁnd a cause-effect relationship
and hence there may be a place for the mechanism-oriented
treatment of CRPS.References
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